Posters
« Back
Revolution to Blood Transfusion: The One-Size-Fits-All Artificial Blood
EP30198
Poster Title: Revolution to Blood Transfusion: The One-Size-Fits-All Artificial Blood
Submitted on 28 May 2019
Author(s): Yi Wen Tay, Geok Fong Ong, Sheh Wen Kuan, Doris Ying Ying Tang, Sweet Mun Wong, Athirah Nurhuda Abdul Razak, Nadia Asyikin Muhammad Rabuan, Nurul Aini Atikah Sidek, Nurain Chow Effandy Chow
Affiliations: Department of Biomedical Science, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia
This poster was presented at University of Malaya
Poster Views: 322
View poster »


Poster Information
Abstract: Blood is a special type of connective tissue comprised of red blood cells (RBC), white cells, platelets and plasma. Although allogeneic RBC transfusions can be life-saving in exsanguinating trauma patients and patients with thalassemia major, adverse events impacting the patients' outcome such as shortage of blood supply and transmission of blood-borne pathogens have been documented. These issues urge for the invention of artificial blood. Perfluorocarbon‐based artificial blood (PFC) is a chemically inert synthetic molecule that consists primarily of carbon and fluorine atoms. PFCs act as artificial oxygen carriers and are designed for the sole purpose of transporting oxygen and carbon dioxide throughout the body. PFCs can physically dissolve significant quantities of oxygen and carbon dioxide. The production of PFCs involves electrochemical fluorination, whereby an organic raw material such as octane sulfonyl fluoride undergoes electrolysis in anhydrous hydrogen fluoride, leading to the replacement of all hydrogen atoms by fluorine atoms. PFCs are hydrophobic due to the strong bond between carbon and fluorine atoms, and thus they are not miscible in water. Consequently, PFCs have to be emulsified for intravenous use. The production of PFCs is relatively inexpensive and can be made without any biological materials. Hence, the clinical use of PFCs can improve tissue oxygenation and eliminate the possibility of blood-borne disease transmission compared to the allogeneic blood transfusion. PFCs can be also used for the treatment of diseases with compromised tissue oxygenation such as cerebral ischemia and emergency or trauma surgery when allogeneic blood is unavailable. In conclusion, PFC is stable, safe, and affordable. Its invention may thereby reduce dependency on allogeneic blood transfusions in surgery and also provide continuous availability of blood supply.Summary: Perfluorocarbon (PFC) is a chemically inert synthetic molecule that acts as artificial oxygen carrier. It can majestically dissolve significant amount of gases such as oxygen and carbon dioxide. In short, it is a safe substitute for blood, reducing the dependency of allergenic blood and thus, providing a continuous supply of bloodReferences: Sarkar S. (2008). Artificial blood. Indian journal of critical care medicine : peer-reviewed, official publication of Indian Society of Critical Care Medicine, 12(3), 140–144. doi:10.4103/0972-5229.43685
Marion Renault. 2019. Searching in vein: a history of artificial blood. Retrieved from: https://www.popsci.com/artificial-blood-history-science
Moradi, S., Jahanian-Najafabadi, A., & Roudkenar, M. H. (2016). Artificial Blood Substitutes: First Steps on the Long Route to Clinical Utility. Clinical medicine insights. Blood disorders, 9, 33–41. doi:10.4137/CMBD.S38461

Report abuse »
Questions
Ask the author a question about this poster.
Ask a Question »

Creative Commons

Related Posters


Genetic Engineering in Male Sterility for Hybrid Variety Development
Abir Hasan Joy

Digiceuticals
Helana Lutfi and Shaban Nuredini

Potential therapeutic effects of induced pluripotent stem cells on induced salivary gland cancer in experimental rats
Yasmine Alaa El-Din1, Dina Sabry2, Amal Hassan Abdelrahman3, and Safa Fathy3

A New Method for the Reliable Detection of 13C Multiplets of Fluorine Containing Compounds
Dimitris Argyropoulos, Rostislav Pol, Vladimir Mikhailenko, and Sergey Golotvin

Investigating orthogonal in vitro analytical approaches to demonstrate bioequivalence (BE) of nasal suspension formulations
Gonçalo Farias, Robert Price, William Ganley, Debbie Huck-Jones, Paul Kippax & Jagdeep Shur